ProfileGDS5678 / 1449214_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 79% 77% 81% 78% 81% 80% 77% 78% 78% 79% 80% 79% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2175177
GSM967853U87-EV human glioblastoma xenograft - Control 25.5806379
GSM967854U87-EV human glioblastoma xenograft - Control 35.2224477
GSM967855U87-EV human glioblastoma xenograft - Control 45.9093881
GSM967856U87-EV human glioblastoma xenograft - Control 55.3683778
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.6743581
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4604680
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.2820877
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4005178
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.3950278
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.5368779
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6807380
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4452879
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5107279